Biologics to treat anaphylaxis.
Journal
Current opinion in allergy and clinical immunology
ISSN: 1473-6322
Titre abrégé: Curr Opin Allergy Clin Immunol
Pays: United States
ID NLM: 100936359
Informations de publication
Date de publication:
01 10 2023
01 10 2023
Historique:
medline:
31
8
2023
pubmed:
1
8
2023
entrez:
1
8
2023
Statut:
ppublish
Résumé
The purpose of this literature review was to review the latest use of biologics in the management of anaphylaxis. The methodology was to highlight both the nonbiologic management of anaphylaxis and the biologic management and how they can be used in conjunction with each other. As the phenotypes and endotypes of anaphylaxis are better portrayed, it furthers our understanding of the mechanisms of anaphylaxis. New applications of existing biologics to the prevention of anaphylaxis are described. Anaphylaxis is a potentially life-threatening acute hypersensitivity reaction affecting up to 16.8% of the U.S. population. Acute management entails swift identification, removal of the causative agent, and the prevention of cardiovascular collapse, firstly with epinephrine. Adjunctive treatments such as antihistamines work to prevent anaphylaxis from recurring. Biologic management of anaphylaxis involves the use of large-molecule drugs such as monoclonal antibodies. Omalizumab, an IgG1 monoclonal antibody targeting unbound IgE, is the most prevalent and widely studied biologic in the prevention of anaphylaxis. Other monoclonal antibodies in development or approved for other indications, such as ligelizumab, quilizumab, MEDI4212, and dupilumab, may also have potential for preventing anaphylaxis through various mechanisms.
Identifiants
pubmed: 37527059
doi: 10.1097/ACI.0000000000000940
pii: 00130832-990000000-00081
doi:
Substances chimiques
Omalizumab
2P471X1Z11
Antibodies, Monoclonal
0
Epinephrine
YKH834O4BH
Immunoglobulin E
37341-29-0
Biological Products
0
Types de publication
Review
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
370-375Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Chaaban MR, Warren Z, Baillargeon JG, et al. Epidemiology and trends of anaphylaxis in the United States, 2004–2016. Int Forum Allergy Rhinol 2019; 9:607–614.
Weiss ME, Adkinson NF. Immediate hypersensitivity reactions to penicillin and related antibiotics. Clin Allergy 1988; 18:515–540.
Castells M. Diagnosis and management of anaphylaxis in precision medicine. J Allergy Clin Immunol 2017; 140:321–333.
Cardona V, Ansotegui IJ, Ebisawa M, et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organ J 2020; 13:100472.
Burzynska M, Piasecka-Kwiatkowska D. A review of honeybee venom allergens and allergenicity. Int J Mol Sci 2021; 22: doi: 10.3390/ijms22168371.
doi: 10.3390/ijms22168371
Yang BC, Castells MC. The who, what, where, when, why, and how of drug desensitization. Immunol Allergy Clin N Am 2022; 42:403–420.
Reber LL, Hernandez JD, Galli SJ. The pathophysiology of anaphylaxis. J Allergy Clin Immunol 2017; 140:335–348.
McNeil BD. MRGPRX2 and adverse drug reactions. Front Immunol 2021; 12:676354.
McNeil BD, Pundir P, Meeker S, et al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature 2015; 519:237–241.
Yang BC, Castells M. Medical algorithm: diagnosis and treatment of drug hypersensitivity reactions to biologicals. Allergy 2020; 75:3293–3296.
Tanno LK, Alvarez-Perea A, Pouessel G. Therapeutic approach of anaphylaxis. Curr Opin Allergy Clin Immunol 2019; 19:393–401.
Rachid O, Simons KJ, Rawas-Qalaji M. In vivo evaluation of taste-masked fast-disintegrating sublingual tablets of epinephrine microcrystals. AAPS PharmSciTech 2018; 19:3886–3894.
Oppenheimer J, Wargacki S, Kainthan R, et al. A phase 1, randomized study evaluating the safety tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of epinephrine prodrug 109 sublingual film (AQST-109) in healthy male volunteers. J Allerg Clin Immunol 2022; 149:AB324.
Dreborg S, Kim H. The pharmacokinetics of epinephrine/adrenaline autoinjectors. Allergy Asthma Clin Immunol 2021; 17:25.
Francuzik W, Dolle S, Worm M. Risk factors and treatment of refractory anaphylaxis − a review of case reports. Expert Rev Clin Immunol 2018; 14:307–314.
Park JH, Godbold JH, Chung D, et al. Comparison of cetirizine and diphenhydramine in the treatment of acute food-induced allergic reactions. J Allergy Clin Immunol 2011; 128:1127–1128.
Lee S, Sadosty AT, Campbell RL. Update on biphasic anaphylaxis. Curr Opin Allergy Clin Immunol 2016; 16:346–351.
Alqurashi W, Ellis AK. Do corticosteroids prevent biphasic anaphylaxis? J Allergy Clin Immunol Pract 2017; 5:1194–1205.
Ghimire A, Olbrecht VA, Tobias JD. Role of sugammadex in the treatment of anaphylaxis due to rocuronium in children: extrapolation from adult and animal reports. Paediatr Anaesth 2022; 32:706–715.
Kim SM, Oh SH, Ryu SA. Treatment of rocuronium-induced anaphylaxis using sugammadex − a case report. Anesth Pain Med (Seoul) 2021; 16:56–59.
Morrow T, Felcone LH. Defining the difference: what makes biologics unique. Biotechnol Healthc 2004; 1:24–29.
Congressional Budget Office, Office CB. Research and development in the pharmaceutical industry. 2021.
Kalorama. What's trending in monoclonal antibodies (markets by structure, by target, and by indication). 2017.
Pajno GB, Fernandez-Rivas M, Arasi S, et al. EAACI guidelines on allergen immunotherapy: IgE-mediated food allergy. Allergy 2018; 73:799–815.
Cardet JC, Casale TB. New insights into the utility of omalizumab. J Allergy Clin Immunol 2019; 143:923–926. e1.
Novartis/Genentech: xolair prescribing information (package insert). Available at: https://www.gene.com/download/pdf/xolair_prescribing.pdf . 2022.
Tanno LK, Demoly P. Biologicals for the prevention of anaphylaxis. Curr Opin Allergy Clin Immunol 2021; 21:303–308.
Fiocchi A, Vickery BP, Wood RA. The use of biologics in food allergy. Clin Exp Allergy 2021; 51:1006–1018.
Palosuo K, Alenius H, Varjonen E, et al. A novel wheat gliadin as a cause of exercise-induced anaphylaxis. J Allergy Clin Immunol 1999; 103 (5 Pt 1):912–917.
Chinuki Y, Kohno K, Hide M, et al. Efficacy and safety of omalizumab in adult patients with wheat-dependent exercise-induced anaphylaxis: Reduction of in vitro basophil activation and allergic reaction to wheat. Allergol Int 2023; 72:444–450.
Okazaki S, Doi K, Momo N, Tanaka Y. Food-dependent exercise-induced anaphylaxis improved by omalizumab prescribed for idiopathic chronic urticaria. Arerugi 2022; 71:46–50.
Salari F, Bemanian MH, Fallahpour M, et al. The effectiveness of oral immunotherapy in patients with sesame anaphylaxis using omalizumab. Clin Med Res 2022; 20:125–132.
MacGinnitie AJ, Rachid R, Gragg H, et al. Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol 2017; 139:873–881. e8.
Gulsen A, Rueff F, Jappe U. Omalizumab ensures compatibility to bee venom immunotherapy (VIT) after VIT-induced anaphylaxis in a patient with systemic mastocytosis. Allergol Select 2021; 5:128–132.
Ridolo E, Pellicelli I, Kihlgren P, et al. Immunotherapy and biologicals for the treatment of allergy to Hymenoptera stings. Expert Opin Biol Ther 2019; 19:919–925.
Kontou-Fili K. High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy 2008; 63:376–378.
Kontou-Fili K, Filis CI. Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis. Allergy 2009; 64:1384–1385.
Kontou-Fili K, Filis CI, Voulgari C, Panayiotidis PG. Omalizumab monotherapy for bee sting and unprovoked ‘anaphylaxis’ in a patient with systemic mastocytosis and undetectable specific IgE. Ann Allergy Asthma Immunol 2010; 104:537–539.
Waldram J, Walters K, Simon R, et al. Safety and outcomes of aspirin desensitization for aspirin-exacerbated respiratory disease: a single-center study. J Allergy Clin Immunol 2018; 141:250–256.
Lang DM, Aronica MA, Maierson ES, et al. Omalizumab can inhibit respiratory reaction during aspirin desensitization. Ann Allergy Asthma Immunol 2018; 121:98–104.
Sanchez-Morillas L, Casado Herraez A, Rubio-Perez M, et al. Usefulness of omalizumab in rapid drug desensitization in patients with severe anaphylaxis induced by carboplatin: open questions. J Investig Allergol Clin Immunol 2020; 30:298–300.
Yong PF, Malik R, Arif S, et al. Rituximab and omalizumab in severe, refractory insulin allergy. N Engl J Med 2009; 360:1045–1047.
Arasi S, Mennini M, Cafarotti A, Fiocchi A. Omalizumab as monotherapy for food allergy. Curr Opin Allergy Clin Immunol 2021; 21:286–291.
Wang J. Management of the patient with multiple food allergies. Curr Allergy Asthma Rep 2010; 10:271–277.
Sampson HA, Leung DY, Burks AW, et al. A phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol 2011; 127:1309–1310. e1.
Singh GK. Omalizumab, a savior in long term prevention of idiopathic anaphylaxis with urticaria: a case series. Dermatol Ther 2021; 34:e15165.
Kaminsky LW, Aukstuolis K, Petroni DH, Al-Shaikhly T. Use of omalizumab for management of idiopathic anaphylaxis: a systematic review and retrospective case series. Ann Allergy Asthma Immunol 2021; 127:481–487.
Carter MC, Maric I, Brittain EH, et al. A randomized double-blind, placebo-controlled study of omalizumab for idiopathic anaphylaxis. J Allergy Clin Immunol 2021; 147:1004–1010. e2.
Jensen RK, Jabs F, Miehe M, et al. Structure of intact IgE and the mechanism of ligelizumab revealed by electron microscopy. Allergy 2020; 75:1956–1965.
Gasser P, Tarchevskaya SS, Guntern P, et al. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nat Commun 2020; 11:165.
Wood RA, Chinthrajah RS, Eggel A, et al. The rationale for development of ligelizumab in food allergy. World Allergy Organ J 2022; 15:100690.
Harris JM, Cabanski CR, Scheerens H, et al. A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria. J Allergy Clin Immunol 2016; 138:1730–1732.
Harris JM, Maciuca R, Bradley MS, et al. A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma. Respir Res 2016; 17:29.
Sheldon E, Schwickart M, Li J, et al. Pharmacokinetics, pharmacodynamics, and safety of MEDI4212, an anti-IgE monoclonal antibody, in subjects with atopy: a phase I study. Adv Ther 2016; 33:225–251.
Nyborg AC, Zacco A, Ettinger R, et al. Development of an antibody that neutralizes soluble IgE and eliminates IgE expressing B cells. Cell Mol Immunol 2016; 13:391–400.
Harb H, Chatila TA. Mechanisms of dupilumab. Clin Exp Allergy 2020; 50:5–14.
Munoz-Bellido FJ, Moreno E, Davila I. Dupilumab: a review of present indications and off-label uses. J Investig Allergol Clin Immunol 2022; 32:97–115.
Otani T, Iwamoto H, Horimasu Y, et al. Effect of dupilumab in a patient with severe asthma complicated with recurrent anaphylaxis: a case report. J Investig Allergol Clin Immunol 2023; 33:230–232.
Bian S, Zhang P, Li L, et al. Anaphylaxis associated with allergen specific immunotherapy, omalizumab, and dupilumab: a real world study based on the US Food and Drug Administration adverse event reporting system. Front Pharmacol 2021; 12:767999.
Borzutzky A, Morales PS, Mezzano V, et al. Induction of remission of idiopathic anaphylaxis with rituximab. J Allergy Clin Immunol 2014; 134:981–983.